| Year |
Citation |
Score |
| 2021 |
Moore TL, Young DA, Killiany RJ, Fonseca KR, Volfson D, Gray DL, Balice-Gordon R, Kozak R. The Effects of a Novel Non-catechol Dopamine Partial Agonist on Working Memory in the Aged Rhesus Monkey. Frontiers in Aging Neuroscience. 13: 757850. PMID 34899271 DOI: 10.3389/fnagi.2021.757850 |
0.506 |
|
| 2020 |
Young D, Popiolek M, Trapa P, Fonseca KR, Brevard J, Gray DL, Kozak R. D1 agonist improved movement of parkinsonian nonhuman primates with limited dyskinesia side effects. Acs Chemical Neuroscience. PMID 31971364 DOI: 10.1021/acschemneuro.9b00589 |
0.532 |
|
| 2018 |
Popiolek M, Mandelblat-Cerf Y, Young D, Garst-Orozco J, Lotarski SM, Stark E, Kramer M, Butler CR, Kozak R. In vivo modulation of hippocampal excitability by M4 muscarinic acetylcholine receptor activator: implications for treatment of Alzheimer's disease and schizophrenic patients. Acs Chemical Neuroscience. PMID 30335349 DOI: 10.1021/acschemneuro.8b00496 |
0.553 |
|
| 2018 |
Howe WM, Brooks JL, Tierney PL, Pang J, Rossi A, Young D, Dlugolenski K, Guillmette E, Roy M, Hales K, Kozak R. α5 nAChR modulation of the prefrontal cortex makes attention resilient. Brain Structure & Function. PMID 29299690 DOI: 10.1007/s00429-017-1601-1 |
0.73 |
|
| 2017 |
Popiolek M, Tierney PL, Young D, Lotarski S, Kozak R. FUNCTIONAL AND PHARMACOLOGICAL CHARACTERIZATION OF A NOVEL AND SELECTIVE MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ACTIVATOR Alzheimer's & Dementia. 13: P946. DOI: 10.1016/j.jalz.2017.06.1857 |
0.531 |
|
| 2016 |
Howe WM, Young DA, Bekheet G, Kozak R. Nicotinic receptor subtypes differentially modulate glutamate release in the dorsal medial striatum. Neurochemistry International. PMID 27568861 DOI: 10.1016/j.neuint.2016.08.009 |
0.721 |
|
| 2015 |
Mohler EG, Ding Z, Rueter LE, Chapin D, Young D, Kozak R. Cross-site strain comparison of pharmacological deficits in the touchscreen visual discrimination test. Psychopharmacology. PMID 26177580 DOI: 10.1007/s00213-015-4012-0 |
0.542 |
|
| 2015 |
Howe WM, Tierney PL, Young DA, Oomen C, Kozak R. MAM (E17) rodent developmental model of neuropsychiatric disease: disruptions in learning and dysregulation of nucleus accumbens dopamine release, but spared executive function. Psychopharmacology. PMID 25963563 DOI: 10.1007/s00213-015-3955-5 |
0.698 |
|
| 2015 |
Howe W, Tierney PL, Rossi A, Young D, Guillmette E, Kozak R. 2.14α5 nAChR modulation of the effects of nicotine on ventral-striatal DA release and cue-reward learning Biochemical Pharmacology. 97: 634-635. DOI: 10.1016/J.Bcp.2015.08.039 |
0.708 |
|
| 2014 |
Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, Chapin DS, McGinnis D, Abbott AL, Roberts BM, Fonseca K, Guanowsky V, Young DA, Seymour PA, Dounay A, et al. Reduction of brain kynurenic acid improves cognitive function. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 10592-602. PMID 25100593 DOI: 10.1523/Jneurosci.1107-14.2014 |
0.574 |
|
| 2014 |
Koshy Cherian A, Gritton H, Johnson DE, Young D, Kozak R, Sarter M. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology. 82: 41-8. PMID 24647121 DOI: 10.1016/j.neuropharm.2014.03.004 |
0.729 |
|
| 2007 |
Briand LA, Gritton H, Howe WM, Young DA, Sarter M. Modulators in concert for cognition: modulator interactions in the prefrontal cortex. Progress in Neurobiology. 83: 69-91. PMID 17681661 DOI: 10.1016/j.pneurobio.2007.06.007 |
0.692 |
|
| 2007 |
Kozak R, Martinez V, Young D, Brown H, Bruno JP, Sarter M. Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 2074-86. PMID 17299502 DOI: 10.1038/sj.npp.1301352 |
0.705 |
|
| Show low-probability matches. |